Home LiteratureArticle Details
PMID: 26061753 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors.

The New England journal of medicine ·Vol. 372 ·No. 26 ·2015-06-25 ·Pages 2499-508

Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, Pekmezci M, Rice T, Kosel ML, Smirnov IV, Sarkar G, Caron AA, Kollmeyer TM, Praska CE, Chada AR, Halder C, Hansen HM, McCoy LS, Bracci PM, Marshall R, Zheng S, Reis GF, Pico AR, O'Neill BP, Buckner JC, Giannini C, Huse JT, Perry A, Tihan T, Berger MS, Chang SM, Prados MD, Wiemels J, Wiencke JK, Wrensch MR, Jenkins RB

Abstract

The prediction of clinical behavior, response to therapy, and outcome of infiltrative glioma is challenging. On the basis of previous studies of tumor biology, we defined five glioma molecular groups with the use of three alterations: mutations in the TERT promoter, mutations in IDH, and codeletion of chromosome arms 1p and 19q (1p/19q codeletion). We tested the hypothesis that within groups based on these features, tumors would have similar clinical variables, acquired somatic alterations, and germline variants. We scored tumors as negative or positive for each of these markers in 1087 gliomas and compared acquired alterations and patient characteristics among the five primary molecular groups. Using 11,590 controls, we assessed associations between these groups and known glioma germline variants. Among 615 grade II or III gliomas, 29% had all three alterations (i.e., were triple-positive), 5% had TERT and IDH mutations, 45% had only IDH mutations, 7% were triple-negative, and 10% had only TERT mutations; 5% had other combinations. Among 472 grade IV gliomas, less than 1% were triple-positive, 2% had TERT and IDH mutations, 7% had only IDH mutations, 17% were triple-negative, and 74% had only TERT mutations. The mean age at diagnosis was lowest (37 years) among patients who had gliomas with only IDH mutations and was highest (59 years) among patients who had gliomas with only TERT mutations. The molecular groups were independently associated with overall survival among patients with grade II or III gliomas but not among patients with grade IV gliomas. The molecular groups were associated with specific germline variants. Gliomas were classified into five principal groups on the basis of three tumor markers. The groups had different ages at onset, overall survival, and associations with germline variants, which implies that they are characterized by distinct mechanisms of pathogenesis. (Funded by the National Institutes of Health and others.).

MeSH Terms
Adult Age of Onset Biomarkers, Tumor Chromosomes, Human, Pair 1 Chromosomes, Human, Pair 19 DNA Mutational Analysis DNA, Neoplasm/analysis Female Germ-Line Mutation Glioma/classification,genetics,mortality Humans Isocitrate Dehydrogenase/genetics Kaplan-Meier Estimate Male Middle Aged Mutation Neoplasm Grading Promoter Regions, Genetic Proportional Hazards Models Telomerase/genetics
Chemicals
Biomarkers, Tumor DNA, Neoplasm IDH2, human Isocitrate Dehydrogenase IDH1 protein, human TERT protein, human Telomerase
Authors & Affiliations
36 authors, click to expand affiliations / ORCID
Eckel-Passow Jeanette E
From the Departments of Health Sciences Research (J.E.E.-P., P.A.D., H.S., M.L.K.), Laboratory Medicine and Pathology (D.H.L., G.S., A.A.C., T.M.K., C.E.P., A.R.C., C.H., C.G., R.B.J.), Neurology (D.H.L., B.P.O.), and Oncology (J.C.B.), Mayo Clinic, Rochester, MN; the Departments of Neurological Surgery (A.M.M., K.M.W., T.R., I.V.S., H.M.H., L.S.M., S.Z., A.P., M.S.B., S.M.C., M.D.P., J.K.W., M.R.W.), Epidemiology and Biostatistics (A.M.M., P.M.B., J.W., J.K.W., M.R.W.) and Pathology (M.P., R.M., G.F.R., A.P., T.T.) and the Institute of Human Genetics (J.W., J.K.W., M.R.W.), University of California, San Francisco, and the Bioinformatics Core, Gladstone Institutes (A.R.P.) - all in San Francisco; and the Department of Pathology and Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York (J.T.H.).
Lachance Daniel H
Molinaro Annette M
Walsh Kyle M
Decker Paul A
Sicotte Hugues
Pekmezci Melike
Rice Terri
Kosel Matt L
Smirnov Ivan V
Sarkar Gobinda
Caron Alissa A
Kollmeyer Thomas M
Praska Corinne E
Chada Anisha R
Halder Chandralekha
Hansen Helen M
McCoy Lucie S
Bracci Paige M
Marshall Roxanne
Zheng Shichun
Reis Gerald F
Pico Alexander R
O'Neill Brian P
Buckner Jan C
Giannini Caterina
Huse Jason T
Perry Arie
Tihan Tarik
Berger Mitchell S
Chang Susan M
Prados Michael D
Wiemels Joseph
Wiencke John K
Wrensch Margaret R
Jenkins Robert B
References (29)
29 references, click to expand
  1. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.
    N Engl J Med. 2015 Jun 25;372(26):2481-98 PMID: 26061751
  2. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis.
    Cancer Cell. 2006 Mar;9(3):157-73 PMID: 16530701
  3. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma.
    Cancer Res. 2006 Oct 15;66(20):9852-61 PMID: 17047046
  4. Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility.
    Nat Genet. 2009 Aug;41(8):905-8 PMID: 19578366
  5. Genome-wide association study identifies five susceptibility loci for glioma.
    Nat Genet. 2009 Aug;41(8):899-904 PMID: 19578367
  6. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.
    Cancer Cell. 2010 Jan 19;17(1):98-110 PMID: 20129251
  7. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.
    Cancer Cell. 2010 May 18;17(5):510-22 PMID: 20399149
  8. Distinct germ line polymorphisms underlie glioma morphologic heterogeneity.
    Cancer Genet. 2011 Jan;204(1):13-8 PMID: 21356187
  9. Mayo Genome Consortia: a genotype-phenotype resource for genome-wide association studies with an application to the analysis of circulating bilirubin levels.
    Mayo Clin Proc. 2011 Jul;86(7):606-14 PMID: 21646302
  10. A germline variant in the TP53 polyadenylation signal confers cancer susceptibility.
    Nat Genet. 2011 Nov;43(11):1098-103 PMID: 21946351
  11. Isocitrate dehydrogenase mutations in gliomas: mechanisms, biomarkers and therapeutic target.
    Curr Opin Neurol. 2011 Dec;24(6):648-52 PMID: 22002076
  12. IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma.
    Clin Cancer Res. 2012 May 1;18(9):2490-501 PMID: 22415316
  13. A low-frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumors and astrocytomas with IDH1 or IDH2 mutation.
    Nat Genet. 2012 Oct;44(10):1122-5 PMID: 22922872
  14. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.
    J Clin Oncol. 2013 Jan 20;31(3):344-50 PMID: 23071237
  15. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.
    J Clin Oncol. 2013 Jan 20;31(3):337-43 PMID: 23071247
  16. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal.
    Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6021-6 PMID: 23530248
  17. Association between glioma susceptibility loci and tumour pathology defines specific molecular etiologies.
    Neuro Oncol. 2013 May;15(5):542-7 PMID: 23161787
  18. Inherited variant on chromosome 11q23 increases susceptibility to IDH-mutated but not IDH-normal gliomas regardless of grade or histology.
    Neuro Oncol. 2013 May;15(5):535-41 PMID: 23361564
  19. Deciphering the 8q24.21 association for glioma.
    Hum Mol Genet. 2013 Jun 1;22(11):2293-302 PMID: 23399484
  20. The somatic genomic landscape of glioblastoma.
    Cell. 2013 Oct 10;155(2):462-77 PMID: 24120142
  21. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH.
    J Clin Oncol. 2014 Mar 10;32(8):783-90 PMID: 24516018
  22. Molecular subtypes of glioblastoma are relevant to lower grade glioma.
    PLoS One. 2014;9(3):e91216 PMID: 24614622
  23. Long-range interaction and correlation between MYC enhancer and oncogenic long noncoding RNA CARLo-5.
    Proc Natl Acad Sci U S A. 2014 Mar 18;111(11):4173-8 PMID: 24594601
  24. Variants near TERT and TERC influencing telomere length are associated with high-grade glioma risk.
    Nat Genet. 2014 Jul;46(7):731-5 PMID: 24908248
  25. Telomerase promoter mutations in cancer: an emerging molecular biomarker?
    Virchows Arch. 2014 Aug;465(2):119-33 PMID: 25048572
  26. PVT1 dependence in cancer with MYC copy-number increase.
    Nature. 2014 Aug 7;512(7512):82-6 PMID: 25043044
  27. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.
    Neurology. 2014 Sep 23;83(13):1200-6 PMID: 25150284
  28. International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading.
    Brain Pathol. 2014 Sep;24(5):429-35 PMID: 24990071
  29. Germline mutations in shelterin complex genes are associated with familial glioma.
    J Natl Cancer Inst. 2015 Jan;107(1):384 PMID: 25482530
Article Info
Journal
The New England journal of medicine
Abbr.
N Engl J Med
ISSN
1533-4406
Published
2015-06-25
Epub
2015-00-10
Pages
2499-508
Language
English
Region
United States
NLM ID
0255562
PMCID
PMC4489704
Subset
IM
Grants
NCI NIH HHS · R01 CA139020 · United States
NCI NIH HHS · R01CA126831 · United States
NCI NIH HHS · P50 CA108961 · United States
NINDS NIH HHS · RC1 NS068222 · United States
NINDS NIH HHS · RC1NS068222Z · United States
NCI NIH HHS · R25 CA112355 · United States
NCI NIH HHS · R01 CA126831 · United States
NCRR NIH HHS · UL1 RR024131 · United States
NCI NIH HHS · P50 CA097257 · United States
NCI NIH HHS · R01 CA163687 · United States
NCI NIH HHS · R25CA112355 · United States
NCI NIH HHS · P30 CA015083 · United States
NCI NIH HHS · P50CA097257 · United States
NCI NIH HHS · R01CA163687 · United States
NCI NIH HHS · P50CA108961 · United States
NCI NIH HHS · R01CA139020 · United States
NCI NIH HHS · R01CA52689 · United States
NCI NIH HHS · P30 CA15083 · United States
NCI NIH HHS · R01 CA052689 · United States
Corrections
CommentIn
CommentIn
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com